Pantoprazole: A new proton pump inhibitor

doi:10.1016/S0149-2918(00)83025-8

Clinical Therapeutics

Volume 22, Issue 11, November 2000, Pages 1268-1293

https://doi.org/10.1016/S0149-2918(00)83025-8 Get rights and content

Abstract

Objective: This paper reviews the pharmacology, clinical efficacy, and tolerability of pantoprazole in comparison with those of other available proton pump inhibitors (PPIs).

Methods: Relevant English-language research and review articles were identified by database searches of MEDLINE®, International Pharmaceutical Abstracts®, and UnCover, and by examining the reference lists of the articles so identified. In selecting data for inclusion, the author gave preference to full-length articles published in peer-reviewed journals.

Results: Like other PPIs, pantoprazole exerts its pharmacodynamic actions by binding to the proton pump (H⁺,K⁺-adenosine triphosphatase) in the parietal cells, but, compared with other PPIs, its binding may be more specific for the proton pump. Pantoprazole is well absorbed when administered as an enteric-coated, delayed-release tablet, with an oral bioavailability of ∼77%. It is hepatically metabolized via cytochrome P2C19 to hydroxy-pantoprazole, an inactive metabolite that subsequently undergoes sulfate conjugation. The elimination half-life ranges from 0.9 to 1.9 hours and is independent of dose. Pantoprazole has similar efficacy to other PPIs in the healing of gastric and duodenal ulcers, as well as erosive esophagitis, and as part of triple-drug regimens for the eradication of Helicobacter pylori from the gastric mucosa. It is well tolerated, with the most common adverse effects being headache, diarrhea, flatulence, and abdominal pain. In clinical studies, it has been shown to have no interactions with various other agents, including carbamazepine, cisapride, cyclosporine, digoxin, phenytoin, theophylline, and warfarin.

Conclusions: Pantoprazole appears to be as effective as other PPIs. Its low potential for drug interactions may give it an advantage in patients taking other drugs.

References (104)

LS Welage et al.
Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases
J Am Pharm Assoc
(2000)
WA Simon et al.
BY 1023/SK&F 96022: Biochemistry of a novel (H⁺,K⁺)-ATPase inhibitor
Biochem Pharmacol
(1990)
JR Pisegna et al.
Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose-response study
Am J Gastroenterol
(1999)
DC Metz et al.
Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease
Am J Gastroenterol
(2000)
EA Lew et al.
Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome
Gastroenterology
(2000)
UG Meneghelli et al.
Pantoprazole versus ranitidine in the treatment of duodenal ulcer: A multicenter study in Brazil
Am J Gastroenterol
(2000)
RJ Adamek et al.
Cure of Helicobacter pylori infection and healing of duodenal ulcer: Comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy
Am J Gastroenterol
(1998)
G Holtmann et al.
Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole
Gastroenterology
(1999)
P Richardson et al.
Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders
Drugs
(1998)
JM Shin et al.
Continuing development of acid pump inhibitors: Site of action of pantoprazole
Aliment Pharmacol Ther
(1994)

G Sachs

Proton pump inhibitors and acid-related diseases

Pharmacotherapy

(1997)

G Sachs et al.

Gastric acid secretion: Activation and inhibition

Yale J Biol Med

(1994)

R Huber et al.

Review article: The continuing development of proton pump inhibitors with particular reference to pantoprazole

Aliment Pharmacol Ther

(1995)

W Kromer

Similarities and differences in the properties of substituted benzimidazoles: A comparison between pantoprazole and related compounds

Digestion

(1995)

A Fitton et al.

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders

Drugs

(1996)

B Simon et al.

Effect of repeated oral administration of BY 1023/SK&F 96022—a new substituted benzimidazole derivative—on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man

Aliment Pharmacol Ther

(1990)

B Simon et al.

Single intravenous administration of the H⁺,K⁺-ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man

Aliment Pharmacol Ther

(1990)

B Simon et al.

Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H⁺,K⁺-ATPase-inhibitor pantoprazole (BY 1023/SK&F96022) in healthy volunteers

Z Gastroenterol

(1990)

V Savarino et al.

Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer

Aliment Pharmacol Ther

(1998)

A Hannan et al.

Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles

Aliment Pharmacol Ther

(1992)

H Koop et al.

Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects

Eur J Gastroenterol Hepatol

(1996)

S Mussig et al.

Morning and evening administration of pantoprazole: A study to compare the effect on 24-hour intragastric pH

Eur J Gastroenterol Hepatol

(1997)

M Hartmann et al.

Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole

Aliment Pharmacol Ther

(1998)

M Hartmann et al.

Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole

Aliment Pharmacol Ther

(1996)

HG Dammann et al.

Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion

Eur J Gastroenterol Hepatol

(1999)

C Florent et al.

Twenty-four-hour monitoring of intragastric acidity: Comparison between lansoprazole 30mg and pantoprazole 40mg

Eur J Gastroenterol Hepatol

(1997)

U Armbrecht et al.

Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole—comparison of 24-hour intragastric and oesophageal pH

Aliment Pharmacol Ther

(1997)

J Mossner et al.

A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial

Aliment Pharmacol Ther

(1995)

J Escourrou et al.

Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis

Aliment Pharmacol Ther

(1999)

(2000)

M Dattilo et al.

Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors

J Clin Gastroenterol

(1998)

S Suerbaum et al.

Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori

Eur J Clin Microbiol Infect Dis

(1991)

T Andersson

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

Clin Pharmacokinet

(1996)

R Huber et al.

Pharmacokinetics of pantoprazole in man

Int J Clin Pharmacol Ther

(1996)

M Tanaka et al.

Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor, after single and multiple oral doses in healthy Japanese volunteers

Int J Clin Pharmacol Ther

(1996)

H Bliesath et al.

Dose linearity of the pharmacokinetics of the new H⁺/K⁺-ATPase inhibitor pantoprazole after single intravenous administration

Int J Clin Pharmacol Ther

(1994)

MA Pue et al.

Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects

Eur J Clin Pharmacol

(1993)

UA Meyer

Interaction of proton pump inhibitors with cytochromes P450: Consequences for drug interactions

Yale J Biol Med

(1996)

M Tanaka et al.

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype

Clin Pharmacol Ther

(1997)

T Andersson et al.

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

Br J Clin Pharmacol

(1998)

P Unge et al.

Drug interactions with proton pump inhibitors

Drug Saf

(1997)

V Kliem et al.

Pharmacokinetics of pantoprazole in patients with end-stage renal failure

Nephrol Dial Transplant

(1998)

M Rehner et al.

Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration—a multicentre study

Aliment Pharmacol Ther

(1995)

JA Beker et al.

Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer

Eur J Gastroenterol Hepatol

(1995)

TS Chen et al.

The efficacy of the third proton pump inhibitor—pantoprazole—in the short-term treatment of Chinese patients with duodenal ulcer

Hepato-Gastroenterology

(1999)

W Schepp et al.

Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study

Scand J Gastroenterol

(1995)

M Cremer et al.

A double-blind study of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicenter trial

Dig Dis Sci

(1995)

G Judmaier et al.

Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer

Aliment Pharmacol Ther

(1994)

L Witzel et al.

Pantoprazole versus omeprazole in the treatment of acute gastric ulcers

Aliment Pharmacol Ther

(1995)

J Hotz et al.

Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer

Scand J Gastroenterol

(1995)

Cited by (76)

Proton pump inhibitor prescribing patterns and utilization: A retrospective chart review analysis
2023, Saudi Pharmaceutical Journal
Proton pump inhibitors (PPIs) show a high level of efficacy and a high safety profile, and they have been increasingly prescribed in recent years. However, recent pharmacoepidemiological evidence has shown that PPI use has been associated with health risks and complications.
This study aimed to assess the prescribing patterns of proton pump inhibitors and the prevalence of potential drug–drug interactions (DDIs) among patients who use PPIs.
This was a retrospective analysis of electronic health records from the Ministry of National Guard Hospitals in Riyadh from January 2019 to June 2022. All adult patients who used PPIs were included to assess the prescribing patterns and drug utilization, including the number of prescriptions, duration of prescriptions, number of doses, and prescription indications. Potential DDIs were assessed based on concurrent use, which is defined as taking an interacting drug parallel to PPIs. The assessment includes complete or partial overlapping, with at least one day of overlapping.
The total number of PPI prescriptions was 80,365 for a total of 9,930 patients with a mean age of 67.5. The majority of PPIs were prescribed in high doses (74%), without reporting appropriate indications (95%), and 17% were prescribed for long-term use. A total of 24,575 (33.6%) potential DDIs with PPIs were found.
The results showed that the majority of the PPI prescriptions were made with a high number of doses, without reporting appropriate indications, with some having potential DDIs. This might result in exposing patients to an increasing number of health risks. The findings highlight the importance of implementing a stewardship program for PPI prescription with periodic reassessments of patients’ needs for these medications.
Solubility enhancement of pantoprazole sodium sesquihydrate through supercritical solvent: Machine learning based study
2023, Journal of Molecular Liquids
Theoretical/experimental measurement and optimization of solubility is considered as an active field of research in different scientific areas such as pharmaceutics. Novel orally administered therapeutic medicines have recently suffered from low solubility and bioavailability. Therefore, finding better methods to improve the drug solubility and bioavailability are of prime importance. Application of CO₂ supercritical fluid (CO₂SCF) as a well-known procedure has attracted numerous attentions in pharmaceutical industry to increase the drug solubility and bioavailability due to its low flammability, reasonable cost, and negligible detrimental impacts for ecosystem. Pantoprazole sodium sesquihydrate is an extensively-used drug, which is indicated for the alleviation of the undesirable signs of esophagitis caused by stomach acid due to gastroesophageal reflux disease (GERD). The purpose of this research is to analyze and optimize the solubility of Pantoprazole sodium sesquihydrate using four different tree-based models where we have temperature and pressure as input features. These models include the regression tree, the boosting model based on it (gradient boosting), the bagging model based on it (random forest), and finally a more recently developed boosting model (extreme gradient boosting). All of these models, after optimization with their hyper-parameters, show an R²-score of more than 0.9. Finally, extreme gradient boosting was selected as the main model of this work, which has a 1.07 × 10^-2 maximum error and an RMSE error rate of 5.85 × 10^-3.
Benzimidazole based hybrids against complex diseases: A catalogue of the SAR profile
2021, European Journal of Pharmacology
The fused heterocyclic ring system has been recognized as a privileged structure that is used as a template in medicinal chemistry for drug discovery. Benzimidazole is one of the common scaffolds found in several natural products such as histidine, purines, and an integral part of vitamin B12. This hetero-aromatic bicyclic ring system acts as a pharmacophore in various drugs of therapeutic interest and has a broad spectrum of activity. Literature reports suggest that diversely substituted benzimidazoles possess distinct pharmacological profiles with multi-targeting potential, thereby, an indispensable anchor for the development of novel therapeutic agents against complex diseases such as cancer, malaria, inflammatory disorders, microbial diseases, hypertension, etc. Thus, lots of efforts have been diverted towards exploring the therapeutic potential of benzimidazoles. Despite great efforts made by the research community, still, some multi-factorial diseases continue to progress due to their complex pathophysiology. Under these sets of circumstances, there is a need to explore this nucleus for hybrid designing with multi-targeting potential against complex diseases. Benzimidazole-based hybrids have been reported to treat multifactorial diseases, making it a scaffold of interest for various pharmaceutical companies and research groups. In this write-up, we shed light on the recent pharmacological profiles, various designing strategies, and structure-activity relationships (SAR) of different benzimidazole-based hybrids.
Peroxidation and photo-peroxidation of pantoprazole in aqueous solution using silver molybdate as catalyst
2021, Chemosphere
Citation Excerpt :
Pantoprazole (PAN) (Fig. S1A) is one of the most commonly consumed drugs worldwide (Ortiz de García et al., 2013), and approximately 70–95% of the consumed PAN is excreted as inactive or pharmaceutically active metabolites in urine and feces (Kosma et al., 2016). PAN residues are present in domestic wastewaters, in concentrations of up to 0.18 μg L−1 (Barreiro et al., 2011; Gracia-Lor et al., 2012), and although PAN species (Fig. S1B) are unstable at acidic pH (Jungnickel, 2000), its removal and/or mineralization by wastewaters treatment plant has not been completely studied. PAN is well removed by adsorption onto iron-based nanoparticles (89% removal in 30 min) (Ali et al., 2016), but the mineralization efficiency through AOPs (e.g. heterogeneous Fenton-like processes using Fe3O4/CeO2) is rather low (Gan et al., 2017).
In this study, silver molybdate was used as a catalyst in different oxidation processes to degrade pantoprazole (PAN) from aqueous suspension. The catalyst was synthesized using a controlled precipitation method and characterized by XRD, FTIR spectroscopy, BET analysis, Zeta potential, FEG-SEM/EDS, DRS and EPR. The α- and β-phases of Ag₂MoO₄ were identified as crystalline structure of the butterfly-shaped particles. The metastable α-phase could be completely converted into β-Ag₂MoO₄ by thermal treatment at 300 °C. The band gap energy of β-Ag₂MoO₄ (E_g = 3.25 eV) is slightly higher than for as-prepared catalyst (α-Ag₂MoO₄ + β-Ag₂MoO₄) (E_g = 3.09 eV), suggesting that as-prepared catalyst should be active under visible light. PAN is sensible to UV light irradiation, and the addition of H₂O₂ as electron acceptor enhanced the mineralization rate. In the catalytic UV-based reactions, high PAN oxidation efficiencies were obtained (>85%) but with low mineralization (32-64%). Catalytic peroxidation and photo-catalytic peroxidation under visible light showed the highest PAN oxidation efficiency, leading to its almost complete mineralization (>95%), even under dark conditions (98% in 120 min). Several degradation byproducts were identified and three mechanistic routes of PAN decomposition were proposed. The identified byproducts are less toxic than the parent compound. EPR coupled with the spin trapping method identified ^•OH radicals as the main ROS species in both photocatalytic and catalytic peroxidation reactions. Ag₂MoO₄ showed to be a promising catalyst to promote the decomposition of hydrogen peroxide into ROS.¹
A new strategy for extraction and depuration of pantoprazole in rat plasma: Vortex assisted dispersive micro-solid-phase extraction employing metal organic framework MIL-101(Cr) as sorbent followed by dispersive liquid–liquid microextraction based on solidification of a floating organic droplet
2019, Journal of Pharmaceutical and Biomedical Analysis
Citation Excerpt :
The method is especially suited to extract organic compounds with relative lower polarity [17]. Pantoprazole is a selective and irreversible proton pump inhibitor for the treatment of acid-related hypersecretory gastrointestinal disorders [18–20]. Up to now, multiple quantitative methods have been established for monitoring the concentration of pantoprazole in plasma.
Dispersive micro-solid-phase extraction (DMSPE) combined with dispersive liquid–liquid microextraction based on the solidification of a floating organic droplet (DLLME-SFO) was successfully developed for extraction and depuration of pantoprazole in rat plasma. The remarkable metal organic framework (MOF), MIL-101(Cr) was used as DMSPE adsorbent. The detection of pantoprazole was performed by convenient HPLC-UV. In the extraction of pantoprazole from plasma samples, small molecule compounds, including the target and abundant impurities, were easily admitted into the porous structure of MIL-101 (Cr) material in DMSPE; while, macromolecular compounds were handily excluded from the adsorbent. Next, the depuration process was achieved by removal of small polar impurities in DLLME-SFO. Influential factors were systematically optimized for ideal enrichment and depuration efficiency. Under the optimal conditions, a satisfactory linearity range from the lower limit of quantification (LLOQ, 100 ng/L) to 10 000 ng/L with the correlation coefficients (r) of 0.9934 was obtained. The LLOQ was 100 ng/mL and the relative recoveries were ≧ 73.2 ± 4.8%. The approving reproducibility, acceptable accuracy, and stability were all within the acceptance limits. This proposed method presented the advantages of environment-friendly, low-cost, recyclable, low impurity, and preferable applicability. It could offer a new idea for the pretreatment and pharmacokinetic study of pantoprazole in rat plasma.
A new pollen-derived microcarrier for pantoprazole delivery
2017, Materials Science and Engineering C
Citation Excerpt :
Pantoprazole (PaNa) is a proton pump inhibitor and widely used for healing of duodenal ulcer, gastric ulcers and gastroesophageal reflux disease. It is effective in reducing acid secretion and elevates pH levels of gastric juice [1,2]. It selectively binds to cysteine residues of H+/K+–adenosine triphosphatase in the apical membrane of the gastric parietal cells, thereby inhibiting acid secretion [3].
Plant-derived carriers have emerged as promising materials for drug encapsulation. Especially, sporopollenin microcapsules extracted from diverse pollen species have been proved to be effective drug carriers due to their biocompatibility, homogeneity in size, resistance to harsh chemical conditions and high thermal stability. Here in this study, sporopollenin microcapsules were isolated successfully from the pollens of a common tree (Corylus avellana, the European hazelnut) and used as a carrier for pantoprazole (PaNa) (a proton pump inhibitor). The drug entrapment efficiency was recorded as 29.81%. SEM micrographs clearly showed the drug was loaded into the microcapsules through the apertures of microcapsule and also some drugs were adsorbed on the surface of microcapsules. FT-IR spectra analysis confirmed the drug loading. Thermogravimetric analysis revealed that thermal stability of PaNa was enhanced by encapsulation. In vitro release studies showed that PaNa-loaded sporopollenin microcapsules exhibited better release performance than the control. C. avellana sporopollenin microcapsules can make an efficient carrier for delivery of PaNa.

View all citing articles on Scopus

View full text

New drugsPantoprazole: A new proton pump inhibitor

Abstract

J Am Pharm Assoc

Biochem Pharmacol

Am J Gastroenterol

Am J Gastroenterol

Gastroenterology

Am J Gastroenterol

Am J Gastroenterol

Gastroenterology

Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders

Drugs

Continuing development of acid pump inhibitors: Site of action of pantoprazole

Aliment Pharmacol Ther

Proton pump inhibitors and acid-related diseases

Pharmacotherapy

Gastric acid secretion: Activation and inhibition

Yale J Biol Med

Review article: The continuing development of proton pump inhibitors with particular reference to pantoprazole

Aliment Pharmacol Ther

Similarities and differences in the properties of substituted benzimidazoles: A comparison between pantoprazole and related compounds

Digestion

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders

Drugs

Effect of repeated oral administration of BY 1023/SK&F 96022—a new substituted benzimidazole derivative—on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man

Aliment Pharmacol Ther

Single intravenous administration of the H+,K+-ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man

Aliment Pharmacol Ther

Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+,K+-ATPase-inhibitor pantoprazole (BY 1023/SK&F96022) in healthy volunteers

Z Gastroenterol

Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer

Aliment Pharmacol Ther

Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles

Aliment Pharmacol Ther

Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects

Eur J Gastroenterol Hepatol

Morning and evening administration of pantoprazole: A study to compare the effect on 24-hour intragastric pH

Eur J Gastroenterol Hepatol

Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole

Aliment Pharmacol Ther

Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole

Aliment Pharmacol Ther

Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion

Eur J Gastroenterol Hepatol

Twenty-four-hour monitoring of intragastric acidity: Comparison between lansoprazole 30mg and pantoprazole 40mg

Eur J Gastroenterol Hepatol

Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole—comparison of 24-hour intragastric and oesophageal pH

Aliment Pharmacol Ther

A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial

Aliment Pharmacol Ther

Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis

Aliment Pharmacol Ther

Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors

J Clin Gastroenterol

Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori

Eur J Clin Microbiol Infect Dis

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

Clin Pharmacokinet

Pharmacokinetics of pantoprazole in man

Int J Clin Pharmacol Ther

Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor, after single and multiple oral doses in healthy Japanese volunteers

Int J Clin Pharmacol Ther

Dose linearity of the pharmacokinetics of the new H+/K+-ATPase inhibitor pantoprazole after single intravenous administration

Int J Clin Pharmacol Ther

Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects

Eur J Clin Pharmacol

Interaction of proton pump inhibitors with cytochromes P450: Consequences for drug interactions

Yale J Biol Med

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype

Clin Pharmacol Ther

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

Br J Clin Pharmacol

Drug interactions with proton pump inhibitors

Drug Saf

Pharmacokinetics of pantoprazole in patients with end-stage renal failure

Nephrol Dial Transplant

Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration—a multicentre study

Aliment Pharmacol Ther

Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer

Eur J Gastroenterol Hepatol

New drugs
Pantoprazole: A new proton pump inhibitor

Single intravenous administration of the H⁺,K⁺-ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man

Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H⁺,K⁺-ATPase-inhibitor pantoprazole (BY 1023/SK&F96022) in healthy volunteers

Dose linearity of the pharmacokinetics of the new H⁺/K⁺-ATPase inhibitor pantoprazole after single intravenous administration